2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Chronic Myeloproliferative Disorders
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
80 Active assets in the Chronic Myeloproliferative Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Evomela Center for International Blood and Marrow Transplant Research | Phase 2/3 | BBB |
Fludarabine Sawa Ito, MD | Phase 4 | BB |
Anti-Thymoglobulin, Rabbit Fred Hutchinson Cancer Center | Phase 2/3 | BB |
Busulphan Sawa Ito, MD | Phase 4 | BB |
Fludarabine Sawa Ito, MD | Phase 4 | BB |
View all 50 →
Same molecule, other indications
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →